Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JAMA Articles Suggest Non-Inferiority Trials Are, In Fact, Sometimes Inferior

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-inferiority and equivalence trials, which have been employed for a number of high-profile trials, are often poorly planned and reported, according to a series of articles in the March 8 issue of the Journal of the American Medical Association.

You may also be interested in...



Quality-Of-Life Data Favor Stenting Over Drugs In Short-Term

The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.

Feds Try To Pave Path For Frustrated Pediatric Device Innovators

NIH and government agencies plan to submit plans to Congress next month describing ways to encourage the development of medical devices for children.

Legal Issues Abound For Device Marketers In The Blogosphere

Do not be cavalier about this venue, drug/device lawyer warns.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel